Sinovant Sciences, a Shanghai-based biopharmaceutical company dedicated to bringing innovative medicines to China and advancing Chinese biopharmaceutical innovation abroad, unveiled its pipeline and leadership team.
CASI Pharmaceuticals, a US-based biopharmaceutical company, will expand its presence in China by entering into a long-term manufacturing agreement with China’s Yiling Wanzhou International Pharmaceutical Co. Ltd
The Johnson & Johnson Institute, a leader in professional medical education, announced the opening of its new facility in Beijing. It represents the largest investment in the global relaunch of the Johnson & Johnson institutes.
WuXi Biologics, a leading global open-access biologics technology platform company, announced that it is to build an integrated biologics development, clinical and commercial manufacturing center in Northern China.
With support in research and development, registration of Chinese generic drugs and marketing of the drugs in the global market, companies will be encouraged by the government to carry out international cooperation.
CMAB Biopharma, a Chinese full-service contract development and manufacturing organization (CDMO) providing process development and manufacturing services for biologic products, raised $34 million fin...